Ecs Botanics Holdings Ltd · ASX:ECS

Ecs Botanics — Investor Presentation (May 2024)

10 slides from Ecs Botanics's investor presentation, May 28, 2024

  1. Slide 1: ECS Botanics Holdings Ltd Investor Webinar

    For personal use only I N V E S T O R W E B I N A R ECS Botanics Holdings Ltd A large-scale organic cultivator and manufacturer of GMP medicinal cannabis products ASX : ECS 28 MAY 2024

  2. Slide 2: Investment Highlights

    ECS Botanics Investment Highlights  Successful Australian Medicinal Cannabis Cultivator For personal use only and Manufacturer based in NW Victoria  Rapidly growing global market ~$80b; ECS addressable M A Y market ~$8-10b 2 0 2 4  Secured contracts with leading global cannabis companies such as

  3. Slide 3: The ECS Advantage

    The ECS Advantage . For personal use only 01 02 03 04 I N V E S T O R Cost Quality Sustainable Australian ECS has a cost The Company has ECS deploys organic, Australian patients and P R E S E N T A T I O N advantage with fit for demonstrated its ability regenerative practices doctors are seeking pur

  4. Slide 4: Large and Growing Addressable Market

    Large and Growing .Addressable Market For personal use only M A Y A Large and Growing Market Doctors and Patients seeking Australian grown products Drug types most involved in 2 0 2 4 poly-substance deaths from 2017–21 Globally the legal cannabis market is $60b and growing. Growth is being driven by

  5. Slide 5: Strategic Roadmap Summary

    Strategic Roadmap Summary Delivering on a Clear Strategy to Drive Value. For personal use only 2018-2020 2021-2023 2024-2026 2027-2029 M A Y Developing Capability Focused, Expanding Drive Profitability, Leading Australian and Confidence and Growing Revenue Innovation and Expansion Medicinal Cannabis

  6. Slide 6: ECS strategy: Leveraging our advantage

    ECS strategy Leveraging our advantage For personal use only Mango Passion Quality dried flower A soothing, earthy aroma lays the foundation for a comforting and grounding experience. Notes of deep forest freshness intermingle with a subtle zest M A Y THC 24% TOTAL TERPENE CONTENT 2.0%  Next generat

  7. Slide 7: ECS strategy: Retail Expansion

    ECS strategy Retail Expansion For personal use only  ECS secured its first B2C medicinal cannabis contract under the 'RAP' brand with a minimum annual value of M A Y $380,000  Launched soft gel caps 2 0 2 4  Attracted some of the most successful Average 17 years in Pharmaceutical sales and experi

  8. Slide 8: The ECS Advantage: Quality, Product Range and Expansion

    The ECS Advantage QualityProduct Range ECS Botanics expands product range. For personal use only  Oils  Dried Flower M A Y  Vapes  Gummies Soft Gel Capsules 2 0 2 4 W E B I N A R   VESIsorb® A NOVEL SELF-EMULSIFYING GMP Licence DRUG DELIVERY SYSTEM  GMP licence has been expanded to include pa

  9. Slide 9: Questions & Answers

    Questions & For personal use only Answers 2021-2023 2024-2026 2027-2029 M A Y 2 0 2 4 W E B I N A R 9 © 2024 ECS Botanics Holdings Limited. Confidential & proprietary.

  10. Slide 10: Disclaimer

    Disclaimer For personal use only E Q U I T Y This presentation has been prepared by ECS Botanics recommendation in relation to the purchase or sales of contractors or agents about the accuracy, completeness Holdings Limited (“Company”). shares or other securities in any jurisdiction. or fairness of

ECS Botanics Holdings — Investor Presentation (May 2024) on 6ix